|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
|
|
|
|
€ 955,00 |
Editeur
: |
Business Insight |
Langue
: |
Anglais |
Date de publication : |
Octobre 2000 |
Taille du document : |
203 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (2) |
|
|
|
| 54 pages | Janvier 2002 | Anglais
|
|
|
| Main
focus: |
aircraft,cns
|
| Research
focus: |
demand analysis,market size and estimates, |
| Geographic
focus: |
usa,mexico,united kingdom |
| |
|
|
|
|
| 51 pages | Février 2007 | Anglais
|
|
|
| Main
focus: |
cns,insomnia,alzheimer,anxiety,antidepressant,...
|
| Research
focus: |
market size and estimates,market outlook, |
| Geographic
focus: |
usa,france |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Healthcare In Northern Ireland
52 pages | Mai 2000 |
The Northern Ireland Presentation Includes:- The Structure Of The Health Service In Northern Ireland- Total Expenditure On Health & Personal Social Services- Number Of Inpatient Beds, BY Area- Occ |
327,00 €
|
| |
| |
The Drug Discovery Outlook: Drivers of innovation in the 21st Century
189 pages | Octobre 2000 |
The Drug Discovery Outlook: Drivers of innovation in the 21st Century introduces and analyzes the five key enabling technologies and bioinformatics, which are currently driving pharmaceutical dru |
955,00 €
|
| |
| |
ePharmacies: Strategic Implications for the Healthcare Industry
230 pages | Mars 2000 |
Increasingly, the pharmaceutical sector is being influenced by the Internet.Are you in a position to:- Predict future shifts in drug prescribing and purchasing behavior?- Anticipate consolidation in b |
955,00 €
|
| |
| |
The Evolution of DTC marketing across key pharmaceutical markets
152 pages | Mars 2000 |
Pharmaceutical companies mainly market their products through contact between their sales force and heathcare providers.
However, due to the nature of its products, the pharmaceutical industry |
955,00 €
|
| |
| |
Healthcare In Scotland
52 pages | Mai 2000 |
The Scottish Presentation Includes:- The Structure Of The NHS In Scotland- The Funding Of The NHS In Scotland- Distribution Of The NHS Budget In Scotland- Segmentation Of Expenditure - Total Capital E |
327,00 €
|
| |
| |
The UK piling Market
40 pages | Mai 2002 |
This report will enable you to:Analyse the size of the UK market for piling between 1997 and 2006Quantify the size of the UK market for piling, 1997-2006, by technique: - bored - driven - embedded |
365,00 €
|
| |
| |
The Pharmacogenomics Outlook
174 pages | Août 2000 |
Pharmaceutical companies are coming under increasing pressure to increase the quality of their products, and optimize and accelerate drug discovery and development.
By identifying differenc |
955,00 €
|
| |
| |
Pharmaceutical Packaging: UK
90 pages | Avril 2000 |
· Analyse the changes in demand for pharmaceutical packaging in the UK, over the next 5 years
· Understand the main factors affecting demand
· Examine the struct |
1 249,31 €
|
| |
| |
Strategic Intelligence: The Top 12 Pharmaceutical Companies
158 pages | Novembre 2001 |
The pressure on the pharmaceutical company R&D has never been greater.
It is estimated that $100 billion worth of products will face patent expiry by 2005.
Of this, $37 billion represe |
1 021,89 €
|
| |
| |
Pharmaceutical Mergers & Aquisitions: the third wave
160 pages | Février 1999 |
Historical assessment : The report identifies the factors that have driven the two historical waves of M&A activity, and analyses the relative importance of these factors through case studies.
795,00 €
|
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
|
|
The Central Nervous System (CNS) market has shown sustained growth in 1999 with
the expansion continuing to be driven by several factors.
A greater understanding of the neuropharmacological mechanisms underlying CNS
disorders has led to the development of more specific and efficacious treatments.
Additionally, physicians now have a greater awareness of both CNS disorders and
the availability of drug therapies for controlling them, and are more likely to
prescribe medications to sufferers.
This has led to the development of a wave of new CNS drug therapies, with improved
side effect profiles and greater efficacy.
The CNS Outlook 2000 provides an analysis of the 1999 performance in the
major CNS markets, (namely Alzheimer's disease, depression, epilepsy, ADHD,
migraine, multiple sclerosis, pain, Parkinson's disease, schizophrenia and stroke),
in addition to an assessment of developing sectors, such as IBS.
Building upon extensive primary research, key market data is allied to competitive
analysis to provide historical and forecast future product sales along with
strategic insight into how companies can exploit opportunities in this market,
whose total value in 1999 neared $50bn.
We have the answers for you:
• Across the CNS market, which products have recorded significant revenues in
recent years?
• How are competing companies positioning themselves within this expanding market?
• In which areas are companies currently focusing their R&D resources?
• Which innovative therapies will reach the market within the next five years
and what will be their impact?
• What are the optimum components of a successful CNS franchise?
• To what extent will generic competition erode market share of branded products?
• What are the major unmet needs in the treatment of CNS disorders and how can
they be targeted?
• To what extent can strategic alliances lessen the financial risk associated
with R&D investment?
|
|
Chapter 1: Patient potential
Chapter 2: Market analysis and forecasts
Chapter 3: Unmet needs
Chapter 4: New market opportunities
Chapter 5: Appendix
|
|
|
PPLSEN
|
|
|
|
|
